Zin Myint

1.3k total citations
62 papers, 659 citations indexed

About

Zin Myint is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Zin Myint has authored 62 papers receiving a total of 659 indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Pulmonary and Respiratory Medicine, 32 papers in Oncology and 15 papers in Surgery. Recurrent topics in Zin Myint's work include Prostate Cancer Treatment and Research (17 papers), Cancer Immunotherapy and Biomarkers (12 papers) and Bladder and Urothelial Cancer Treatments (9 papers). Zin Myint is often cited by papers focused on Prostate Cancer Treatment and Research (17 papers), Cancer Immunotherapy and Biomarkers (12 papers) and Bladder and Urothelial Cancer Treatments (9 papers). Zin Myint collaborates with scholars based in United States, Spain and Italy. Zin Myint's co-authors include Kyaw Zin Thein, Aung M. Tun, Thein Hlaing Oo, Hayder Saeed, Gaurav Goel, Derek B. Allison, Jill Kolesar, Rishi Raj, Aasems Jacob and Donglin Yan and has published in prestigious journals such as Journal of Clinical Oncology, Blood and International Journal of Molecular Sciences.

In The Last Decade

Zin Myint

52 papers receiving 652 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Zin Myint United States 12 207 200 144 106 96 62 659
Kyaw Zin Thein United States 14 220 1.1× 383 1.9× 190 1.3× 114 1.1× 88 0.9× 91 920
Konrad Pawełczyk Poland 14 191 0.9× 196 1.0× 228 1.6× 79 0.7× 122 1.3× 33 634
Hirofumi Hamano Japan 16 156 0.8× 162 0.8× 225 1.6× 69 0.7× 115 1.2× 74 845
Jiexian Jing China 12 108 0.5× 225 1.1× 217 1.5× 106 1.0× 185 1.9× 31 694
Nooshin Mirkheshti United States 10 212 1.0× 120 0.6× 155 1.1× 48 0.5× 116 1.2× 21 462
Yuya Horinouchi Japan 19 231 1.1× 98 0.5× 250 1.7× 122 1.2× 106 1.1× 42 890
Manuel Díez‐Alonso Spain 16 213 1.0× 294 1.5× 225 1.6× 109 1.0× 71 0.7× 91 918
Manuel Macı́a Spain 16 147 0.7× 111 0.6× 199 1.4× 121 1.1× 114 1.2× 35 1.2k
Xianwen Zhao China 10 87 0.4× 184 0.9× 179 1.2× 105 1.0× 141 1.5× 15 582

Countries citing papers authored by Zin Myint

Since Specialization
Citations

This map shows the geographic impact of Zin Myint's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zin Myint with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zin Myint more than expected).

Fields of papers citing papers by Zin Myint

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zin Myint. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zin Myint. The network helps show where Zin Myint may publish in the future.

Co-authorship network of co-authors of Zin Myint

This figure shows the co-authorship network connecting the top 25 collaborators of Zin Myint. A scholar is included among the top collaborators of Zin Myint based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zin Myint. Zin Myint is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Teplitsky, Seth, Joon Kyung Kim, Derek B. Allison, et al.. (2025). Prognostic significance of pathologic response to neoadjuvant chemotherapy in muscle-invasive urothelial carcinoma of the bladder with histologic subtype. Urologic Oncology Seminars and Original Investigations. 43(9). 521.e19–521.e27.
2.
Ratan, Aakrosh, Michelle L. Churchman, Laura Graham, et al.. (2025). Clinical and Genomic Features of Androgen Indifferent Prostate Cancer. International Journal of Molecular Sciences. 26(2). 679–679. 1 indexed citations
3.
Allison, Derek B., et al.. (2025). Case report series: Pembrolizumab and enfortumab vedotin in plasmacytoid urothelial carcinoma. Frontiers in Oncology. 15. 1608291–1608291.
4.
Kim, Joon Kyung, Andrew James, Ravshan Burikhanov, et al.. (2025). Hydroxychloroquine effects on tumor suppressor PAR-4 levels in patients with oligometastatic prostate cancer: Results from a phase-2 trial.. Journal of Clinical Oncology. 43(5_suppl). 233–233. 1 indexed citations
5.
Hussain, Maha, Masha Kocherginsky, Parminder Singh, et al.. (2024). A pilot study of tazemetostat and pembrolizumab in advanced urothelial carcinoma (ETCTN 10183).. Journal of Clinical Oncology. 42(16_suppl). 4574–4574. 2 indexed citations
6.
Kohli, Manish, Gregory Riedlinger, Eric A. Singer, et al.. (2024). Activity of Platinum Chemotherapy in Men With Prostate Cancer With and Without DNA Damage Repair Mutations. Clinical Genitourinary Cancer. 23(1). 102293–102293. 1 indexed citations
7.
Gebrael, Georges, Yeonjung Jo, Umang Swami, et al.. (2024). Bone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer. JAMA Network Open. 7(7). e2419966–e2419966. 4 indexed citations
8.
Myint, Zin, William H. St. Clair, Stephen E. Strup, et al.. (2024). Phase II trial of ArtemiCoffee for men with biochemical recurrence of prostate cancer after local therapy.. Journal of Clinical Oncology. 42(4_suppl). TPS350–TPS350.
9.
Myint, Zin, William H. St. Clair, Stephen E. Strup, et al.. (2023). A Phase I Dose Escalation and Expansion Study of Epidiolex (Cannabidiol) in Patients with Biochemically Recurrent Prostate Cancer. Cancers. 15(9). 2505–2505. 6 indexed citations
10.
Monteiro, Fernando Sabino Marques, Ondřej Fiala, Francesco Massari, et al.. (2023). Systemic Immune-Inflammation Index in Patients Treated With First-Line Immune Combinations for Metastatic Renal Cell Carcinoma: Insights From the ARON-1 Study. Clinical Genitourinary Cancer. 22(2). 305–314.e3. 4 indexed citations
11.
Allison, Derek B., et al.. (2023). Primary mediastinal seminoma presenting with paraneoplastic anti-Hu encephalitis: a case report and literature review. Frontiers in Oncology. 13. 1156566–1156566.
12.
Chen, Quan, et al.. (2023). Disparities in prostate cancer survival outcomes in Appalachian Kentucky.. Journal of Clinical Oncology. 41(6_suppl). 39–39.
13.
14.
Rizzo, Alessandro, Veronica Mollica, Andrea Marchetti, et al.. (2022). Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study. Cancers. 14(17). 4142–4142. 10 indexed citations
15.
Santoni, Matteo, Fernando Sabino Marques Monteiro, Francesco Massari, et al.. (2022). Statins and renal cell carcinoma: Antitumor activity and influence on cancer risk and survival. Critical Reviews in Oncology/Hematology. 176. 103731–103731. 15 indexed citations
16.
Myint, Zin, Ramon C. Sun, Patrick J. Hensley, et al.. (2021). Evaluation of Glutaminase Expression in Prostate Adenocarcinoma and Correlation with Clinicopathologic Parameters. Cancers. 13(9). 2157–2157. 15 indexed citations
17.
Kunos, Charles A., R. E. Howells, Aman Chauhan, et al.. (2021). Radiopharmaceutical Validation for Clinical Use. Frontiers in Oncology. 11. 630827–630827. 14 indexed citations
18.
Myint, Zin, et al.. (2019). Ten-year survival outcomes for patients with early stage classical Hodgkin lymphoma. Hematology/Oncology and Stem Cell Therapy. 13(1). 17–22. 6 indexed citations
19.
Myint, Zin, et al.. (2018). Long-Term Outcomes in Patients after Discontinuation of Immune Checkpoint Inhibitors. 1(3). 1 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kyaw Zin Thein Breakdown of academic impact, for papers by Konrad Pawełczyk Breakdown of academic impact, for papers by Hirofumi Hamano Breakdown of academic impact, for papers by Jiexian Jing Breakdown of academic impact, for papers by Nooshin Mirkheshti Breakdown of academic impact, for papers by Yuya Horinouchi Breakdown of academic impact, for papers by Manuel Díez‐Alonso Breakdown of academic impact, for papers by Manuel Macı́a Breakdown of academic impact, for papers by Xianwen Zhao
Rankless by CCL
2026